Skip to main content

Table 3 Outcomes by antiviral drug

From: Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study

  

Molnupiravir

Remdesivir

  

(n = 57)

(n = 16)

Age, median (range)

 

55 (19–74)

62 (27–74)

Gender, n (%)

   
 

Male

36 (63)

7 (44)

 

Female

21 (37)

9 (56)

Hospitalization, n (%)

 

9 (16)

16 (100)

Disease progression, n (%)

 

8 (14)

2 (13)

Adverse events, n (%)

 

1 (2)

4 (25)

 

Liver dysfunction ( ≦ G2)

―

3 (19)

 

Acute kidney injury (Stage 1)

1 (2)

1 (6)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us